

(19) (12) (KR) (A)

(51) 。 Int. Cl.<sup>7</sup> (11) 10-2004-0099348  
C12P 41/00 (43) 2004 11 26

(21) 10-2004-7014868  
(22) 2004 09 21  
2004 09 21  
(86) PCT/US2003/008941 (87) WO 2003/083126  
(86) 2003 03 21 (87) 2003 10 09

(30) 60/366,767 2002 03 22 (US)  
(71) 48674 1790  
(72) , , .  
92024 818  
, , .  
48642 4608  
, , .  
48642 5001  
, , .  
77566 111  
,  
48642 3919  
(74)

:  
(54) ( )

, ( ) 가  
가 ; , 가  
가 , 가 ( ) ;  
가 , 가 ;

( ) , , , 가 , , 가 , , ,

( ) ( )

(enantiomer) 2 , 2

가 4 3 ( ) 가 가

가 가 3 'R' ( 'D') , 가

'S' ( 'L') , 가 , . 가

2 , 가

(+ ) (-) R, S ( (levarotatory) 'l', ' - ' ) (dextrorotatory) 'd', ' + ' ).

(+ ) (-) 가 (+/-) 'd, l' .

가 가

( ) 2 (resolution)

( 가 )

3 가

가 ( , )

1,2- (Hoff et al. (1996) Tetrahedron: Asymmetry 7:3181-3186).

LC NMR

가 ( - )

( 6,239,316 B1; EPO 99115154.9).

( ) .

가 .

가 . (

$\pm$ )-1- -2- 가 (Baumann et al. (2000) Tetrahedron: Asymmetry 11:4781-4790). ( *Candida antarctica* ) B (CAL-B)가 (R)-1- -2- (50%) 99% ee (R)- 50 M $\ell$  5.28% (w/v)

1- -2- (S)- (20 mmol , 1.0 mg/M $\ell$  50 mg ) 2.7% (w/v) ( $\pm$ )-1- -2- 98% ee 20% (R)-1- -2- 가 (Baumann et al. (2000) Tetrahedron: Asymmetry 11:4781-4790).

CAL-B (Novozyme 435) 4- -2- (R)-(+)-4- -2- 가 95% e ( 6,239,316 B1; EPO 99115154.9).

e (R)- .

( , 1- -2- ) 1- -2- ) .3 , ( (R)- (S)-1- -2- ( JP 1991-262377, JP 1991-262378 JP 1991-262379); (Yanase et al. (1993) Biosci. Biotech. Biochem. 57:1334-1337). , 1- -2- 가 CAL-B (Hoff et al. (1996) Tetrahedron: Asymmetry 7:3181-3186). 1- -2- 2- (Anthonsen et al. (1995) Tetrahedron: Asymmetry 6:3015-3022; Hoff et al. (1996) Tetrahedron: Asymmetry 7:3187-3192). 1- -2- ( 3% w/v) (PLE) (Gais et al. (2001) J. Org. Chem. 66:3384-3396).

가 ( )

가 ,

n- , t- n- , ,

n- 가 가 .

( ) ( )

가 . , ( )

' B' CALB CAL-B .  
 ' U .  
 ' ee .  
 ' E .  
 ' ( 1- -2- ) PM .  
 ' ( 1- -2- ) PMA .  
 ' (1- -2- ) PE .  
 ' (1- -2- ) PEA .  
 ' n- (1-n- -2- ) PnP .  
 ' n- (1-n- -2- ) PnPA .  
 ' (1- -2- ) PiP .  
 ' (1- -2- ) PiPA .  
 ' n- (1-n- -2- ) PnB .  
 ' n- (1-n- -2- ) PnBA .  
 ' tert- (1-tert- -2- ) PtB .  
 ' tert- (1-tert- -2- ) PtBA .  
 ' (1- -2- ) PPh .  
 ' (1- -2- ) PPhA .  
 ' 'P- 'P- ( )  
 , , PM, PE, PnP, PiP, PnB, PtB PPh , .  
 ' 'P- 'P-  
 BA PPhA ( ) , , PMA, PEA, PnPA, PiPA, PnBA, Pt  
 1- ' C-2 '2- .  
 ' ( ) ' PGAE .  
 ' ( ) ' PGAEA .  
 ' ( ) ' -PGAE , PGAEA .  
 ' BA .  
 '4- ' EPA .  
 ' EtA .



가 20% (10% 5% 2% )

R- 30% )가 20% 10% ( S- )가 , R

S- ) ( , 가

'E' 1 E 가 , 20 'E

가 가

E 가 : (ee<sub>s</sub>), (ee<sub>p</sub>)  
 (c) 가 가 (Hydrolases in Organic Synthesis, Bornscheuer, UT and Kazlauskas, RJ (1999) Wiley-VCH, New York, section 3.1.1; and Chen et al., J. Am. Chem. Soc. 104: 7294-7299 (1982)):

$$E = \ln [1 - c(1 + ee_p)] / \ln [1 - c(1 - ee_p)]$$

$$E = \ln [(1 - c)(1 - ee_s)] / \ln [(1 - c)(1 + ee_s)]$$

$$E = \ln \{ (1 - ee_s) / [1 + (ee_s / ee_p)] \} / \ln \{ (1 + ee_s) / [1 + (ee_s / ee_p)] \}$$

CAL-B ( ) 가

(PEA), n- (PnPA), (PMA), (EA),

(BA) (EPA) ( )

, S- - 1-

(BA), ( )

(EPA), (EtA), (EtCA),

(EtFA), (IPA), (VA), (VP), PMA PnPA (EMA)

(TfEB), (DK),

, 2,2,2-


(%)

, GAE) ( , PGAE ) ( , PGAEA P  
 가  
 가  
 1 ( , )  
 0 100% 가  
 '2 ( 가 ) 2  
 , 2 2가 2  
 , ( ) 3% )  
 3% ), 1 (

75% ee 99% ee 30% 50% ( 80% 가 ),  
 ; 80 ,


가

(R S)- 가



, R


$\text{CH}_3)_3$ ,  $\text{C}_6\text{H}_5$ ,  $\text{CH}_3$ ,  $\text{CH}_3$ ,  $\text{CH}_2$ ,  $\text{CH}_3$ ,  $(\text{CH}_2)_2$ ,  $\text{CH}_3$ ,  $(\text{CH}_2)_3$ ,  $\text{CH}(\text{CH}_3)_2$ ,  $\text{C}$   
 가, B, LP 'S', E001, E002, E003  
 가 (Thermogen Inc.) (PLE) 10% v/v, 20% v/v, 30%  
 , 50%가 가, 70% ee  
 R- S- S-  
 가, 5% v/v II R-  
 R-



, R  
 CH<sub>3</sub>)<sub>3</sub> II C<sub>6</sub>H<sub>5</sub> R  
 CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C  
 , 2,2,2- , 2,2,2- , 1- ,  
 , 1- -2- (PMA), (PEA),  
 (EPA) (PnPA), (EA), (BA)  
 가 가 가  
 B, LP 'S', 가  
 (PLE) B 100% v/v  
 50%가 50%가  
 70% ee 30%  
 , R- R- S-  
 (a) (b) (c) (d)



1 1 2 2 ' ' 가  
1 1 ' 1  
, 1

 $\langle \quad || \rangle$ 

The diagram illustrates a complex chemical structure, likely a polymer or a large molecule, featuring a central backbone with multiple branches. The structure includes various functional groups and substituents, such as 1,2,2-trichloroethyl, 2,2,2-trichloroethyl, 1,1,1-trichloroethyl, and 1,1,1-trichloro-2,2,2-trifluoroethyl groups. The diagram is labeled with 'R' and '100%'.

[illegible]

(PLE) . , B (R) - (R) -

1, 가

(a) II 가 , , , ,  
1- -2- (R)-1- -2- ; 80 (S)-

(b) -2- ; (a) (S)-1- -2- (R)-1-


(c) (b) (S)-1- -2- , 5-15 % , 5-10 % ,  
p- (S)-1,  
2- ;



가 .


- 1 ( ) .
- 2 GC/FID (S)-PMA ( )  
 , pH 7.2) CAL-B (1.0 mg/Mℓ L-2 lyo.) 25% (v/v) PMA .  
 PM, 2.81 ; PMA-S, 4.10 ; PMA-R, 4.24 .
- 3 (S)-PMA CAL-B PMA 25% (v/v)  
 L-2 lyo. 0.1 mg/Mℓ ( ) , 0.5 mg/Mℓ ( ) , 1.0 mg/Mℓ ( ) 2.0  
 mg/Mℓ ( ) .
- 4 , L-2, c.-f., C2 가 (a) (±)-1- -2- (PM) (b) (±)-1-  
 -2- (PPh) . (R)-PM (R)-PPhA (% ee)  
 (%) 35% 45% PM/VA (75:25, % v/v) PPh/VA (80:20, % v/v)  
 , L-2, c.-f., C2 (mg/  
 Mℓ) .
- 5 CAL-B (1 mg/Mℓ) 30% (v/v) PPh 70% (v/v)
- 6 PEA 가 . PEA (% ee ) CAL-B 3가  
 ; , 3 (48 ) 8 13 (60 )  
 24 .
- 7 PEA 가 . PEA (% ee )  
 ;  
 2 9 가 . 1.5 l , PEA 20% v/v ,  
 CAL-B , 8, 10, 16 25 ,  
 가 . ( 가 1  
 0%) 가 .
- 8 32 PEA 가 (S)-PEA (R)  
 -PE (% ee ) (% ee )  
 1.5 l , PEA 20% v/v , CAL-B 가 ,  
 ) , ( 7  
 ) , .

&lt; I&gt;



CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub>, C<sub>6</sub>H<sub>5</sub>.

< II >



CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub>, C<sub>6</sub>H<sub>5</sub>.

( I ) ( 1 ) II

( ) 40%, 50% ) 90% ,  
( , ) 95% ) ( ee ) ,

가 ( ) ( , ) 97.5% S- 2.5% R- ( , )  
(S)- 97.5% R- 2.5% S- ( ) 가  
(S)- 가 (S)- 가

( ee (E)  
( 5,541,080 ).

, 110 가 ( , , )  
(v/v) PMA 가 , (±)-PMA [(±)-1- -2- ] 0.5%  
, 1- -2- (PM)  
가 ( , , 2 , ) 가  
5 ).

110 가 (S)- (99 % ee ) B (CAL-B)가  
- 3 ) (R)- PMA [(±)- -2- ( CAL-B  
(S)-PM ( ) 6 ). PM (R)-PMA PMA  
( PM CAL-B ) , , , ,  
가

110 가 가 (±)-1- -2- 가  
(PnPA), (±)-1- -2- (PEA), (±)-1-n- -2-  
(PnBA) (±)-1- -2- (PiPA), (±)-1-n- -2-  
P- (PPhA) (PMA , B (CAL-B)가 가

A (CAL-A) ( 1-5 (CRL) ). (PSL),  
 가  
 , CAL-B ( , PE, PnP, PiP, PnB, PtB PPh (R)- 가  
 , (S)- 가  
 , 2가 ( ) ( )  
 ) 가 가 , 가 2가  
 .  
 ) , 가 ( ) 가 가 ( )  
 가 가 , 가 가 CAL-B  
 가 S- ( ) , S R 가  
 R- ( ) ( ) S- ( )  
 R- ( ) .  
 , ( ) 가  
 ,  
 가 CAL-B R 가 S- R- ( )  
 , S 가 S- ( )  
 ) R- ( ) .  
 , ( )  
 ) 가 가 ( )  
 ) 가 ( )  
 B (CAL-B) 가 ( )  
 .  
 , ( )  
 ) 가 ( )  
 , , , ( )  
 .  
 B (CAL-B) . 가 ( )  
 )  
 가 , , (GC)  
 , 가 ( 1 ).  
 ,  
 50% ( ) , 가 100% ,

ee . ee , 100% .

ee (99% ee ) 50% 가 40-50% 가 .

가 .

가 .

---

( )

( ) 가 가 , 가

50% ( 가 ) ,

50% 55% ee , 95% ee 70% ee 98% ee , 80% ee 85% ee R- , 가 가 .

가 가 . 가 1-5 , B, , , 가 가 .

( ) ( ) ,

가 ,

50% ( ) ,

50% 80% ee 85% ee R- 55% ee , 95% ee 70% ee 98% ee ,

가 가 . 가 1-5 , B, , , 가 가 .

가 가 . 가 가 , 가 가 ,

B (CAL-B) . 가 ,

B (CAL-B) (Patkar et al. (1993) Ind J. Chem. Sect. B 32B: 76-80) ( , NOVO Nordisk SP 52 5; Roche Molecular Biochemicals CHIRAZYME.RTM.L-2.Iyo) . CAL-B , 가 ( , Nov o Nordisk NOVOZYM.RTM.435; Roche L-2, c.-f., Iyo, ( 1); Roche L-2, c.f., C2 ( 2)) , 가 ; .

CAL-B 가 ( , CAL-B )  
 . , CAL-B

가\_\_\_\_\_

( )

가

가

가

가

PMA

가

30%

50%

90% ee

70% ee

95% ee

80% ee

CAL-B

>99% ee

50%

10%

( )

( )

( )

1

( )

0.5%

50% v/v

가

( )

( , PGAEA)

가

40%,

20

25%; PPhA,

15%

2

50%,

10%; PEA,

0.5

25%; P

nPA, PiPA, PnBA,

0.5%

50%,

10

25%.

( )

(mg/Mℓ)

가

C

AL-B (

)

Mℓ

0.5

2 mg

CAL-B

, 가

Mℓ

0.001

5 mg

Mℓ

1

2

mg CAL-B

.

가

CAL-B (

Mℓ

0.1 mg

1 g

Mℓ

1 mg

200 mg

CAL-B

.

0.5 mg

CAL-B

0.5 g

가

,

가

.

pH

2

1

pH

2

pKa

pH

.

5.0, 6.0

7.0

-

가

M , pH 3 가 가 pH 가 , 25 mM pH 200 m  
 2 ( ) ( 가 )  
 , 2 2 2 가 ,  
 가 가  
 2 , 25% 65% (v/v) 가 , 40% 50% (v/v)  
 ) , , 0.25% 10% v/v) 가  
 가 가 가  
 , 가 , 25% (v/v) PMA 1.0 0.5 mg/  
 M CAL-B ( L-2 Iyo) 40 가 30 50 (5 )  
 , PMA 가 35 가 40  
 (S)-PMA . 50 5  
 Iyo) 가 40 가 , CAL-B ( L-2  
 , 35 40 , 35 37 가  
 , ,  
 가 , 50% 가 2 10% (v/v) PMA 가  
 B ( L-2 Iyo, 120 U/mg Iyo. ) 1.0, 0.5, 0.1, 0.05, 0.01, 0.001 mg/M CAL-  
 가 , 0.01 mg/M (S)- 2 , 1.0 0.5 mg/M  
 . 72 , (S)-PMA 98% ee  
 , (S)-PMA 가 가 (S)-PMA 99.5% ee  
 (S)-PMA 25% 10% (50% 0.5 1.0 mg/M ).  
 , 가 25% (v/v) PMA  
 2.0, 1.0 0.5 mg/M CAL-B ( L-2 Iyo.)가 4, 6 24  
 (S)-PMA ( ) 4 ).  
 99% ee , 0.1 mg/M CAL-B ( L-2 Iyo.) 30 (S)-PMA  
 (<60% ee).  
 4 , PMA 2 72 가 , 4 2  
 8 10 , PEA  
 , 가 ; 가  
 , 가 가 ( ) ( 6, 7 11 ). 가





, , , , , 1-  
 , , , , 2 , , ,  
 ( ) 가 , 가 .  
 가 , 가  
 (PMA)가 , 1- -2-  
 (EPA), (EtA) PnPA가 가 (BA), 가  
 가 .  
 ,  
 가 .  
 가 .  
 가 .  
 가 .  
 n- 가 .  
 , 가 , .  
 , 가 , .  
 5% , 가 0.5% 85% ,  
 ) 가 ) ( , ( ,  
 가 100% (v/v) ,  
 , ( ) ) 30% (v/v) 7  
 0% (v/v) ( , 100% ( 70% (v/v) 30% (  
 v/v)) ( , )  
 ( ) 가 , 가 ( ,  
 ) ,  
 , 1% (v/v) 3% (v/v) 가 , 가  
 , , 가 가 ,  
 가 가 ,  
 가 가 .  
 , 2가 ,  
 PGAE ,  
 , 2가 , PGAE ( , )  
 , ( , PGAE) 가 ,

가 .

( PGAE) 50% , 가 (

( CAL-B R- ) , 50%

1 (50% 45%), 2

1 (50% 55%) 1

가 2 가 1

( ) ( , PGAE) 2:1 50%

1 2 1

1/2

1 2

( ) 90% ee 가 35% 65%

( ) 가

( ) 가 1

2 , CAL-B PPh , 70/30 (v/v) 75%

45% , (S)-PPh (R)-PPhA 가 80% ee 98.5% ee

76/24 (v/v)

55%

(R)-PPhA 가 98% ee (S)-PPh 가 60% ee 40%

% ee

GC HPLC ( ,

( ) 45% 55%

( )

10% 90% (v/v)

100% (v/v) , 2

0% 80% (v/v) , 100% (v/v)

PM CAL-B

가 가 가 -20 30

20 30 25 가 , PPh

가

2 96 4 72 가

4 48

가 가

가

가

가

가

가 ,  
가

) 가

, CAL-B

L-2 c.-f. C2 Iyo. (Roche)

가 25%

CAL-B PPhA

가

. PPhA

99% ee

(S)-PPhA

(R)-PPh

25% v/v

PPhA

가

99% ee

(R)-PPh

50%가

75% ee

50%

24

45%

CAL-B

25% (v/v) PPhA

가

(S)-PPhA

(R)-PPh

L-2, c.-f. C2 (

가 : 30, 60

120 U/M $\theta$ )

20% (v/v)

가

PEA 가

( 8 6 )

CAL-B (

L-2, c.-f. C2, Iyo.; Roche

)

120 U/ml

가

25% PMA

30

(

)

(S)-PMA

20%

25%

30

97 % ee

CAL-B (

L-2, c.-f. C2;

240 U/M $\theta$ )

1.5

25% PMA

15

가

.

2.5

6

.

3

7

, 200 rpm

(

) 20% (w/v)

가

7

pH

CAL-B (

L-2, c.-f. C2;

240 U/M $\theta$ )

20% (v

/v) PEA

30

,

가

(

7

7

9

). (~1

8

(S)-PEA

(R)-PE

가

.

가

(~1

0%

가 )

8, 10, 16

25

(S)-PEA

95% ee

(R)-PE

.

. 32

PMA

97.9% ee

(S)-PEA

(R)-PE

.

(

)

-

,

99% ee

(S)-PMA

85% ee

(R)-PM

가

가

(R)-PM

98% ee

95% ee

(S)-PEA

(R)-PE

, 15 PMA 가 32 PEA 가  
(antipodal) .

(Hoff et al. (1996) Tetrahedron: Asymmetry 7: 3181-3186)

가 . , , ( )  
) - 가 . ,  
, , ,  
, , (CIDR) . 가 ,  
, 가  
( ) , TiC14 가 . 가  
(Sharpless)

가 : N ( ); M ( ); mM ( );  $\mu$  M ( ); mol ( );  
mmol ( );  $\mu$  mol ( ); nmol ( ); pmol ( ); g ( ); mg ( );  $\mu$ g ( ); ng  
( ); L ( ); mL ( );  $\mu$ L ( ); cm ( ); mm ( );  $\mu$ m ( ); nm  
( ); U ( );  
( ); % C (% ); ee ( ); E ( ).

1

P- . :

( 1- -2- , PM).

( 1- -2- , PMA).

(1- -2- , PE).

(1- -2- , PEA).

n- (1-n- -2- , PnP).

n- (1-n- -2- , PnPA).

(1- -2- , PiP).

(1- -2- , PiPA).

n- (1-n- -2- , PnB).

n- (1-n- -2- , PnBA).

t- (1-tert- -2- , PtB).

t- (1-tert- -2- , PtBA).

(1- -2- , PPh).

(1- -2- , PPhA).

creen) <sup>TM</sup> EH (Altus Biologics Inc. (Cambridge, MA) ), (Chirazyme)( ) amp  
; 2, G (Roche Molecular Biochemicals (Mann  
heim, Germany; US distribution via BioCatalytics Inc., Pasadena, CA) ), <sup>TM</sup> <sup>TM</sup> (Therm  
oCat <sup>TM</sup> QuickScreen <sup>TM</sup> ) (Thermogen Inc. (Lemont, IL) ),  
B (Fluka BioChemika AG (Buchs, Switzerland) )  
(Amano Pharmaceutical Co. (Nagoya, Japan) ), (Novo Nordisk),  
(Genencor International (Rochester, NY) ) . 4 -20

(HPLC- ), (KH<sub>2</sub>PO<sub>4</sub> , 99.0% min.)  
(Na<sub>2</sub>HPO<sub>4</sub> , 99.0%) (Fisher Scientific) . (S)-  
( T67893, 607). 29.  
6 mol% KH<sub>2</sub>PO<sub>4</sub> 70.4 mol% Na<sub>2</sub>HPO<sub>4</sub> x H<sub>2</sub>O , pH 7.2 .  
/ (Sigma-Aldrich)  
: PM (99.5%), PMA (99.5%), PEA (95%), PnP (99%), PnB (99%), PtB PPh (93%, 7% )  
) ; DPPh ). PE, PiP, PiPA, PnPA, PnBA, PPhA  
( ) (The Dow Chemical Company) . PtBA  
- PtB (1:2 ) 5 mg/Mℓ L-10 (Roche Molecul  
ar Biochemicals)

가 가 가 GC  
가 . , P-

, (S)-PM (S)-PMA ( 2 ), GC , (S)-PM (S)-PMA  
2  
, (S)-PMA가 (R)-PMA ( 4.1 4.24 ),  
가 - (S)-PM (R)-PM .  
P-

(S)-PE (S)-PEA, (S)-PnP (S)-PnPA, (S)-PnB (S)-PnBA, (S)-PPh (S)-PPhA가 ),  
( ) GC PE, PEA, PnP, PnPA, PnB, PnB  
A, PPh PPhA (S)- 가 1- -2- (

(FID) LEAP-CTC (100)가 -  
 6890 GC P- 5가 GC  
 GC  
 (Supelco) -DEX 325 (30 m x 0.25 mm ID 0.25  $\mu$ m  
 PM PMA 70 120 10 /  
 150 18.0 psi ( )  
 200 250 200:1 25:  
 1 (1.0  $\mu$ l). 0.005  
 0.5%  $r^2 > 0.99$

PE, PnP, PiP, PnB, PPh  
 (S)- (R)- (±)-PM  
 : (±)  
 -PM (2.811 ), (S)-PMA (4.104 ), (R)-PMA (4.246 ), (S)-PE (3.203 ), (R)-PE (3.248 ), (S)-PEA (4.774 ), (R)-PEA (4.936 ), (S)-PnP (4.157 ), (R)-PnP (4.224 ), (S)-PnPA (6.0 ), (R)-PnPA (6.145 )  
 , (S)-PiP (3.629 ), (R)-PiP (3.718 ), (S)-PiPA (5.316 ), (R)-PiPA (5.448 ), (S)-PnB (5.394 ), (R)-PnB (5.484 ), (S)-PnBA (7.42 ), (R)-PnBA (7.545 ), (S)-PtB (5.559 ), (R)-PtB (5.908 ), (S)-PtBA (7.529 ) (R)-PtBA (7.679 ).

(±)-PM 20.0 psi ( ) 50 150 10 /  
 -Dex 120 (30 m x 0.25 mm ID 0.25  $\mu$ m ) (Sup  
 elco ) 200 250  
 200:1 25:1 (1.0  $\mu$ l). (S)-PM  
 (R)-PM 3.136 3.192

4 LC (DAD), 200 가 - (Pe  
 rkin-Elmer) 200 DOWANOL ( ) PPh (1- -2- ; PPh)  
 (PPhA) 10/40/50 / /  
 0.65 Ml/ 35 가 OD-RH (4.6 x 150 mm; Chir  
 al Technologies, Inc., Exton, PA) , (R)-PPh, (S)-PPh, (R)-PPhA (S)-P  
 PhA 6.0 , 7.3 , 12.6 13.1 GC-  
 PPh PPh ee , PPh PPhA (  
 ) (DPPH; PPh 7% ) , DPPH

## 2

(S)-PM (S)-PMA

(S)-1- -2- [(S)-PM]

3 100 Ml , 가 / ,  
 가 (22.99 g) (0.0322 g)  
 가 45 (S)-  
 (S)-PO; T67893, Chirex 607] 5 Ml  
 가 12.19 g PO GC ( )  
 PO가 (PM ) 가  
 0.0294 g KOH 가 50 15 가 GC 0.007%  
 (S)-PO PM 150 가  
 PM 91 118 15 Ml  
 가 GC 95.4% 1- -2- (PM-2) 3.2% 2- -1-  
 (PM-1)

(S) - PO	가	가	(Ege, 1989), P
M - 2			(S) - .
, PM - 1		C2	(R) - .

(S) - 1 - - 2 - [(S) - PMA]

25 Me 가 4.0 g (0.044 mole) (S)-PM-2/(R)-PM-1 0.02 g 가  
 118 2 4.7 g (0.046 mole) 1% GC- 가  
 PMA-2 1 PMA-2 가 (S)- 1 PMA-2  
 1 PMA-2 가 (R)-2- -1- PMA-1  
 가 PMA-2 (R) (S) PMA-1  
 2.44 g (0.024 mol) 가 CO<sub>2</sub> 1  
 5.0 g 가 GC 가 95% 95-137  
 1: 2.7%). (S-PMA-2: 92.6% R-PMA-

## 3

PMA 가 :

110 가 PMA 가 .

PMA  
0.5% (v/v)  
가  
가  
30 ( )  
가  
0.8 M  
GC-FID ( ).

가  
(10%  
300 rpm  
가 )  
1.0 mg/M  
0.2 M  
1.8 M  
1

0.065 M KNaPO<sub>4</sub> (pH 7.2)

, PMA , 110 가  
 B (CAL-B)가 PMA (R)- [(R)-1- -2- ; (R)-PMA]  
 가 99% ee가 (S)-PMA ( 1  
 ; PMA 가 ). CAL-B  
 L-2, Iyo., (Roche), 13 (Altus Biologics, Inc.), SP-435 (Novo No  
 CAL-B (Fluka BioChemika) . CAL-B  
 가 L-2, Iyo. (Roche) .  
 , (80% ee  
 ) (Chirazyme L-6, Iyo; Roche),  
 (Fluka Biochemika), PS-C 1 (Amano) (Altus Biologi  
 cs, Inc) ( 1). CAL-B E001, E002  
 E003 (Thermogen, Inc.) .

[ 1 ]

		( )	(S) - PMA (% v/v)	(R) - PMA (% v/v)	PMA (% ee)
1	L-2, Iyo	B	0.0642	0.0001	99.7% S



		(Roche Molecular Biochem.)			
33	SP-435	B (Novo Nordisk)	0.0593	0.0001	99.7% S
49	13	B (Altus Biologics, Inc.)	0.0775	0.0001	99.7% S
106	B,	B (Fluka Biochemika)	0.0732	0.0001	99.7% S
91	LP 'S'	(Amano)	0.0666	0.0001	99.7% S
115		(Fluka Biochemika)	0.0567	0.0001	99.6% S
5	L-6	(Roche Molecular Biochem.)	0.0594	0.0050	84.5% S
95	PS-C I	(Amano)	0.0894	0.0157	70.1% S
38	2	(Altus Biologics, Inc.)	0.0707	0.0186	58.3% S
66	E001	(Thermogen, Inc.)	0.0043	0.0431	81.9% R
67	E002	(Thermogen, Inc.)	0.0001	0.0208	99.0% R
68	E003	(Thermogen, Inc.)	0.0082	0.0476	70.6% R
<sup>1</sup> GC/FID 20 0.5% PMA 1.0 mg/Mℓ 1:5 % / (% v/v) .					

4

가 :

( , ) 가 , (가  
, ) , 가  
가 .

가 0.5 Mℓ 가 1.8 Mℓ  
L-2, Iyo., B, 120 U/mg Iyo , CAL-B ( 30  
(300 rpm) . 10% (v/v)  
1:100 . P- 가  
CAL-B 가  
.  
2 ( 0.5)  
2 가  
가  
2 가

가

2

2

CAL-B ( L-2) (PMA) 가 2  
10% (v/v) PMA 0.5 (50% v/v) C  
AL-B ( 가 10% 50% (v/v) PMA 30 16 , GC  
% (v/v) , (S)-PMA 50% (v/v) PMA . 50  
(S)-PMA 가  
(S)-PMA 가  
(S)-PMA 가 99% ee  
(S)-PMA 10% (v/v) PMA 99% ee  
(S)-PMA .

2 가 PMA

가 2  
PMA 가 10% 25% (v/v) 가 50% (v/v) (S)-PMA  
40% 가 99% ee 87% ee 66% ee . 50% PMA 25%  
(S)-PMA  
(25% 65%, v/v) 10 25% v/v  
50% (v/v) PMA 가  
10% (v/v) PMA가 (S)-PMA 99% ee 20% (v/v)  
) PMA , (S)-PMA 93% ee .

10% amp; 25% PMA 가 PM

CAL-B ( L-2)가 PM , PM 가  
PMA 가  
15% (v/v) 가 PM 10% (v/v) PMA 가 ;  
99,5% ee (S)-PMA 2 , 20% (v/v) PM  
가 PM 가 (0 50%) 25% (v/v) PMA 가 ~96% ee  
12.5% PM  
(S)-PMA  
가 25% (v/v)  
pH 3.5 4.5 ,  
pH 가 ( ).

( , Indlekofer, M. et al. (1996) Biotechnology and Bioengineering, 52:459-471; and Indlekofer, M. et al. (1995) Biotechnology Progress 11:436-442 ).

가

50% (v/v) PMA 1 mg/Mℓ CAL-B ( L-2 Iyo.) 2 (25% (v/v) )  
 0, 66 200 mM (pH 7.2) 44 PMA 가  
 3% ee 84% ee (S)-PMA 18 가 9  
 5, 4.0-4.5 4.5 , 66 mM 200 mM pH 3.0-3.

2 가 가 PMA  
 2 (0.2 n- ) 가 PMA  
 CAL-B ( L-2 Iyo.) % ee 1 mg/Mℓ  
 99.5% ee (S)-PMA 25% (v/v) PMA 64  
 . 30% (v/v) 40% (v/v) PMA 97.5% ee 95.5% ee (S)-P  
 MA . 20% (v/v) 2 PMA , 98.5% ee , 97% ee 가 92% e  
 : 20% (v/v), 25% (v/v) 40% (v/v) 가 PMA 64  
 e (S)-PMA .  
 PMA가 가 가 , 25% (v/v) PMA  
 가 가 ( 2 ).

50% 2 PMA 가  
 50% (v/v) 가 2 10% (v/v) PMA 가  
 mg ) 1.0, 0.5, 0.1, 0.05, 0.01, 0.001 mg/Mℓ CAL-B ( L-2 Iyo., 120 U/  
 2 , 1.0 0.5 mg/Mℓ 가 PMA (S)- 9  
 8% ee . 72 , 0.01 mg/Mℓ 가 (S)-PMA 9  
 9.5% ee . , 0.5 1.0 mg/Mℓ (S)  
 -PMA 25% 10% 가 가 (50%).  
 , 가 25% (v/v) PMA  
 3 . 2.0, 1.0 0.5 mg/Mℓ CAL-B ( L-2 Iyo.)가 4, 6 24  
 99% ee (S)-PMA ( 3). , 0.  
 1 mg/Mℓ CAL-B ( L-2 Iyo.) 30 (S)-PMA (<60% ee  
 ).

PMA  
 2.0 5.0 mg/Mℓ CAL-B ( L-2 Iyo.) 25% (v/v) 50% (v/v) PMA  
 가 .  
 2.0 5.0 mg/Mℓ 가 6 40% (v/v) PMA 가  
 95% ee (S)-PMA . 30 (S)-PMA % ee  
 가 , CAL-B 가 (R)-PMA 가  
 .

PMA 가  
 30 50 (5 ) PMA 25% (v/v) 1.0 0.5 mg/Mℓ CAL-B ( L-  
 2 Iyo.) , PMA 가 가 40 가 35  
 . , 가

(S)-PMA

50 5 40

가 가 가 , CAL-B ( L-2 Iyo.)

가 40 , 35

5

가 P- 가

가 :

PMA 가 110 가 가

P- 2 , 0.5% (v/v) . 2가

4 4 24 , PMA GC , 가

PEA, PnPA, PiPA PnBA (S)- ( 1 ).

가 가 가 ' (his)'

(S)- 85% ee (R)- 가

E001, E002 E003 (Thermoge

n, Inc.)

가 ~2 mg/ml 0.5%, 10%, 25% (v/v)

0.5 M

PEA, PnPA, PiPA PnBA 가 가

2-5 가 CAL-B B (CAL-B)가

), 13 (Altus Biologics, Inc.), SP-435 (Novo Nordisk) L-2, Iyo., (Roche

CAL-B (Fluka BioChemika)

[ 2 ]

	( )	R - PE % ee (% v/v)	S - PEA % ee (% v/v)	E <sup>2</sup> (% C)
B,	B (Fluka Biochemika)	91.50% (7.16)	98.74% (6.52)	113 (53)
L - 2, Iyo	B (Roche Molecular Biochem.)	85.19% (8.94)	98.45% (7.99)	60 (54)
13	B (Altus Biologics, Inc.)	88.81% (6.66)	98.44% (6.01)	81 (54)
SP - 435	B (Novo Nordisk)	95.93% (8.46)	97.11% (6.95)	205 (55)
	(Fluka Biochemika)	49.92% (6.60)	97.61% (4.20)	12 (67)
PS - C II				

	(Amano)	88.98% (8.01)	91.35% (7.49)	55 (52)
2	(Altus Biologics, Inc.)	90.09% (8.90)	88.52% (8.26)	57 (52)
PS	(Amano)	90.43% (6.84)	87.64% (6.64)	57 (50)
	B (Fluka Biochemika)	92.22% (5.31)	74.12% (5.68)	55 (46)
L - 6	(Roche Molecular Biochem.)	93.40% (5.03)	57.12% (6.19)	52 (40)
<sup>1</sup> GC/FID 24 PEA 10% (v/v) 2.0 mg/Mℓ 1:10 % (v/v) <sup>2</sup> $E = \ln((1 - ee\% \text{ PEA}) / (1 + ee\% \text{ PEA} / ee\% \text{ PE})) / \ln((1 + ee\% \text{ PEA}) / (1 + ee\% \text{ PEA} / ee\% \text{ PE}))$ % , %C: $[(S)PE + (R)PE] / [(S)PEA + (R)PEA + (S)PE + (R)PE] \times 100$				

[ 3 ]

	( )	( )	R - PnP % ee (% v/v)	S - PnP % ee (% v/v)	E <sup>2</sup> (% C)
L - 2, Iyo	B (Roche Molecular Biochem.)	4	99.07% (12.86)	95.53% (6.13)	827 (67)
, L - 2, c. - f., C2, Iyo	B	1	98.84% (6.88)	92.86% (3.24)	587 (67)
		4	96.33% (6.96)	91.14% (2.59)	171 (72)
L - 6	(Roche Molecular Biochem.)	4	92.79% (7.22)	73.16% (4.58)	59 (59)
LP S	(Amano)	1	80.46% (7.39)	94.45% (5.96)	33 (57)
		4	50.12% (9.36)	90.42% (2.98)	9 (80)
<sup>1</sup> GC/FID , (300 rpm) 30 PnP 10% (v/v) 2.0 mg/Mℓ 1:100 % (v/v) . 1a 53.2 mg/Mℓ . <sup>2</sup> , ' (E): E = ln((1 - ee% PnP)/(1 + ee% PnP/ee% PnP))/ln((1 + ee% PnP)/(1 + ee% PnP/ee% PnP)) % , %C : [(S)PnP + (R)PnP]/[(S)PnP + (R)PnP + (S)PnP + (R)PnP] x 100					

[ 4 ]

	( )	( )	R-PIP % ee (% v/v)	S-PIPA % ee (% v/v)	E <sup>2</sup> (% C)
L-2, Iyo	B (Roche Molecular Biochem.)	24	94.4% (3.10)	94.14% (2.32)	149 (54)
, L-2, c.-f., C2, Iyo	B (Roche Molecular Biochem.)	1	96.5% (3.39)	98.76% (1.16)	287 (60)
L-6	(Roche Molecular Biochem.)	24	94.86% (3.03)	84.42% (2.25)	102 (56)
L-10	(Roche Molecular Biochem.)	24	94.8% (2.99)	79.0% (2.3)	90 (54)
19	(Altus Biologics)	1	94.46% (3.16)	95.5% (3.06)	135 (51)
LP S	(Amano)	1	95.47% (3.02)	95.27% (2.89)	164 (51)
PS	(Amano)	24	95.64% (3.14)	94.12% (2.31)	160 (57)
<sup>1</sup> GC/FID , (300 rpm) 30 PiPA 10% (v/v) 2.0 mg/Ml 1:100 % (v/v) . 1a 53.2 mg/Ml . <sup>2</sup> ' (E): $E = \ln((1 - ee\% \text{ PIPA}) / (1 + ee\% \text{ PIPA} / ee\% \text{ PnP})) / \ln((1 + ee\% \text{ PIPA}) / (1 + ee\% \text{ PIPA} / ee\% \text{ PIP}))$ % , %C: $[(S)\text{PIP} + (R)\text{PIP}] / [(S)\text{PIPA} + (R)\text{PIPA} + (S)\text{PIP} + (R)\text{PIP}] \times 100$					

[ 5 ]

	( )	( )	R-PnB % ee (% v/v)	S-PnBA % ee (% v/v)	E <sup>2</sup> (% C)
L-2, Iyo	B (Roche Molecular Biochem.)	4	99.95% (3.10)	96.5% (2.81)	>500 (52)
, L-2, c.-f., C2, Iyo	B (Roche Molecular Biochem.)	4	99.95% (2.24)	98.29% (1.16)	>500 (66)
L-6	(Roche Molecular Biochem.)	4	87.01% (2.88)	81.19% (2.89)	36 (49)
L-8	(Roche Molecular Biochem.)	24	99.95% (1.8)	75% (1.05)	>500 (60)
2		24			

				91.26%	63.64%	42.1
				(1.97)	(1.17)	(59)
	(Altus Biologics)					
1	GC/FID			(300 rpm) 30		
	PnBA 10% (v/v)	2.0 mg/Mℓ		1:100		
	% (v/v)	1a	53.2 mg/Mℓ			
2			(E):			
	$E = \ln((1 - ee\% \text{ PnBA}) / (1 + ee\% \text{ PnBA} / ee\% \text{ PnP})) / \ln((1 + ee\% \text{ PnBA}) / (1 + ee\% \text{ PnBA} / ee\% \text{ PnB}))$					
	%		, %C:			
	$[(S)\text{PnB} + (R)\text{PnB}] / [(S)\text{PnBA} + (R)\text{PnBA} + (S)\text{PnB} + (R)\text{PnB}] \times 100$					
500	E	>500				

CAL-B PEA, PnPA, PiPA PnBA ( 2-5 ),

L-2, Iyo L-2, c.-f., C2, Iyo PPhA

가 . 1.0 mg/Mℓ L-2, Iyo. 26.6 mg/Mℓ L-2, c.-f., C2, Iyo PPhA

10, 15, 25, 35 50% (v/v) 0.2 Mℓ PPhA 가

. L-2, c.-f., C2, Iyo. (S)-PPhA (R)-PPh 가 25%

가 99% ee (50% ) . (S)-PPhA 35% (81% ee) 50%

(74% ee) 가 L-2, Iyo 10% 가 (99% ee )

(S)-PPhA , 15%, 25%, 35% 50% (v/v) 가 PPhA가 95

% ee, 86% ee, 79% ee 69% ee .

CAL-B

P- CAL-B ( L-2 Iyo.)

가 6 .

[ 6 ]

	(v/v%)	( )	<sup>1</sup> (mg/Mℓ)	( )	(%)	(R)- % ee	(S)- % ee
PMA	20	40	26.6	4	37.6	n.d.	>99
	20	40	26.6	20	48.9	n.d.	>99
	25	40	26.6	2	35.6	n.d.	>99
	25	40	26.6	30	54.9	n.d.	97.0
	35	40	26.6	22	38.7	n.d.	95.1
	45	40	26.6	22	34.2	n.d.	94.0
	50	40	26.6	30	33.4	n.d.	92.2
	75	40	26.6	6.5	29.3	n.d.	79.1
PEA	10	40	26.6	1.5	53.2	97.3	98.7
	20	40	26.6	3	55.2	96.4	97.1
	25	40	26.6	1.5	56.2	97.3	95.3
	30	40	26.6	3	51.7	96.8	94.6
	35	40	26.6	5	54.4	96.9	93.3
	40	40	26.6	5	51.1	97.3	91.7
	50	40	26.6	20	43.2	97.1	88.2
PnPA	15	30	26.6	4	73.2	>99	91.4

	25	30	26.6	4	59.6	>99	89.7
	35	30	26.6	4	63.2	>99	86.0
	50	30	26.6	24	55.6	>99	80.3
PiPA	15	30	26.6	24	66.2	95.4	90.2
	25	30	26.6	24	68.1	96.4	89.2
	35	30	26.6	24	55.6	97.3	85.6
	50	30	26.6	24	42.1	97.4	79.7
PnBA	15	30	26.6	4	81.7	97.9	93.6
	25	30	26.6	4	50.4	98.9	87.5
	35	30	26.6	4	48.5	>99	83.5
	50	30	26.6	4	47.8	>99	76.9
PPhA	10	30	26.6	4	50.0	>99	>99
	15	30	26.6	4	68.6	>99	>99
	25	30	26.6	4	50.6	>99	>99
	35	30	26.6	24	44.8	>99	81.5
	50	30	26.6	24	41.3	>99	73.7
<sup>1</sup> B, L-2, c.-f., C2, Iyo (~10 U/mg, Roche Molecular Biochemicals) n.d.							

CAL-B가 PEA, PnPA, PiPA, PnBA PPhA  
(R)-가

가 (S)-  
CAL-B가

가

CAL-B (50% 70% v/v)

가

7

7

[ 7 ]

	( )	CAL-B	CAL-B	CAL-B		
		(% v/v)		(% v/v)	가	
PMA	4 (>110)	0.5 - 70	120 - 180 U/Mℓ	25	120 U/Mℓ	30
PEA	12 (>110)	0.5 - 50	15 - 120 U/Mℓ	20	120 U/Mℓ	16
PnPA	8 (>110)	0.5 - 50	120 - 240 U/Mℓ	10	240 U/Mℓ	n.d.
PiPA	7 (>110)	0.5 - 50	120 - 240 U/Mℓ	10	240 U/Mℓ	n.d.
PnBA	8 (>110)	0.5 - 50	120 - 240 U/Mℓ	10	240 U/Mℓ	n.d.
PPhA	2	0.5 - 50	120 U/Mℓ	15	120 U/Mℓ	5
n.d.						



6

: 가

CAL-B PM

( )  
0.5 Mℓ

CAL-B 가

5.0 mg/Mℓ CAL-B ( L-2 Iyo.) 10% (v/v) PM

8

[ 8]

/	PM (% v/v)	PM (% v/v)	(S) - PMA (% v/v)	(R) - PMA (% v/v)	(R) - PMA (% ee)
	10%	1.15	9.40	12.48	14%
/ (8:1)	10%	0.08	11.06	12.20	5%
/ (8:1)	10%	0.09	8.92	9.98	6%
/ (8:1)	10%	6.85	0.62	3.70	71%
	10%	5.80	0.86	9.19	83%
1	16	GC/FID			

16 CAL-B가 ( 8 ). 가 가 PM  
90% (v/v)  
가 가 ,  
가 5.0 mg/Mℓ CAL-B ( L-2 Iyo.)가  
50% (v/v) PM  
A 1 98% ee 50% (v/v) PM , (R) - PM  
가 P-  
가

CAL-B 가 P-

P- PM, PE, PnP, PiP, PnB PPh CAL-B  
(R) -  
가

7

:

), (% ee ( ), 가 ( ), 가 ,  
가

가

75/25% (v/v) PM/VA 80/20% (v/v) PPh/VA / 1.0 Mℓ , PM PPh  
26.6, 13.3 6.7 mg/Mℓ PMA PPhA (R)-가  
B ( L-2, c.-f., C2, lyo.)  
가 % ee가  
PM  
(R)-PMA (R)-PPhA ~10%  
(R)-PPhA % ee 4 가 (R)-PM  
(6.6 mg/Mℓ)

PM 가 가 9

PM CAL-B 가

-20 30

75/25% 70/30% (v/v) PM/ 1.0 Mℓ , PM  
30, 20, 4 -20 (±2) 26.6, 13.3, 6.7, 3.3 1.7 mg/Mℓ  
B ( L-2, c.-f., C2, lyo.)  
% ee (R)-PMA 가  
가 9

[ 9 ]

		/	( )	가 <sup>1</sup> (mg/Mℓ)	( )	(%)	(S)- % ee	(R)- % ee
PM	VA	75/25	30	26.8	2	44.6	n.d.	90.34
				26.8	8	44.8		82.32
PM	VA	70/30	4	26.8	4	20.7		95.3
				26.8	24	53.6		87.6
PM	VA	70/30	-20	26.8	4	8.3		97.6
				26.8	52	45.5		96.3
PM	VA	75/25	30	13.4	2	37.3		93.2
				13.4	8	45.9		88.7
PM	VA	70/30	4	13.4	4	15.3		96.5
				13.4	26	51.9		91.7
PM	VA	70/30	-20	13.4	4	5.7		98.0
				13.4	52	35.5		97.7
PM	VA	75/25	30	6.8	2	24.3		94.7
				6.8	8	46.9		91.7
PM	VA		20	6.8	6	24.5		92.1
				6.8	22	42.4		87.7
PM	VA		4	6.8	6	20.0		96.6
				6.8	48	46.0		93.0

PM	VA		-20	6.8	6	5.5		98.4
				6.8	48	26.3		97.9
PM	VA	75/25	30	3.4	2	12.1		94.4
				3.4	6	25.5		92.5
PM	VA		20	3.4	6	17.8		93.5
				3.4	22	32.9		91.3
PM	VA		4	3.4	6	11.4		97.0
				3.4	48	40.4		94.6
PM	VA		-20	3.4	6	2.6		98.5
				3.4	48	14.6		98.3
PM	VA	75/25	30	1.7	2	6.7		94.8
				1.7	6	23.1		92.6
PM	VA		20	1.7	6	11.0		94.6
				1.7	22	30.2		92.8
PM	VA		4	1.7	6	6.3		97.3
				1.7	48	30.1		96.3
PM	VA		-20	1.7	6	1.6		98.3
				1.7	48	9.8		98.4
<sup>1</sup> B, ( L-2, c.f., C2, Iyo (~10 U/mg, Roche Molecular Biochemicals) )								

\_\_\_\_\_

( <3% ) PM PPh

( ) ,

\_\_\_\_\_

CAL - B 10 50 150 (E) , 70 % (v/v)

PM, PE, PnP, PiP, PnB PPh

[ 10]

	( )	(S) -OH % ee	(R) -OAc % ee	E
PE	6	37%	96%	71
PnP	5	95%	89%	65
PiP	6	92%	87%	49
PnB	4	>99%	82%	59
PPh	4	>99%	94%	160
<sup>1</sup> 0.5 Mø , 1.0 mg/Mø , 70% (v/v) ,				

(R)-  
5  
(R)-  
(R)-

(CAL-B  
, 50%  
, PEA  
80% ee  
(

, PPhA  
96% ee  
, 87%, 89%  
, 82% ee

; PPh  
ee  
, P-  
PnBA

50%  
, (R)-  
(R)-

가	6.6 mg/M	L-2, c.-f., C2, Iyo.,	PE	1.0
5%	55% (v/v)	1.0 M	PE, PnP 1:1 1:2	3
	PnP	가 (BA),	31% 59% (v/v)	(EtA),
	(EtCA),	(EtFA),	(IPA),	
(VA),	(EMA), 2,2,2-	(TfEB),	(DK)	
(VP)	30	24	(S)-	
(R)-	% ee	%	11	

[ 11 ]

	<sup>1</sup>	/ (v/v)	( )	<sup>2</sup> (mg/Mø)	( )	(%)	(S)- ee (%)	(R)- ee (%)
PE	BA	47/53	30	6.7	20	16.9	11.7	94.9
	BA	47/53	30	6.7	24	17.8	9.5	94.7
	EPA	39/61	30	6.7	20	2.1	- 1.5	51.0
	EtA	54/46	30	6.7	20	17.5	9.8	94.3
	EtA	54/46	30	6.7	24	18.4	3.1	96.7
	ETFA	42/58	30	6.7	20	1.0	- 9.4	15.6
	IPA	51/49	30	6.7	20	51.6	72.4	95.6
	IPA	51/49	30	6.7	24	54.5	77.5	95.3
	VA	55/45	30	6.7	20	44.7	51.8	95.2
	VA	55/45	30	6.7	24	47.4	54.9	95.0
	EMA	47/53	30	6.7	24	1.0	10.7	11.6
	TFEB	38/62	30	6.7	20	60.6	54.5	63.9
	TFEB	38/62	30	6.7	24	63.9	58.7	65.0
	VP	51/49	30	6.7	20	62.5	73.2	67.3
	VP	51/49	30	6.7	24	65.3	77.9	67.8
PnP	BA	50.5/49.5	30	6.7	2	7.4	5.2	98.4
	BA	50.5/49.5	30	6.7	20	17.2	17.4	96.1
	BA	34/66	30	6.7	6	17.1	16.4	97.6
	BA	34/66	30	6.7	24	24.1	23.9	94.9
	EtA	58/42	30	6.7	4	11.4	9.5	98.1
	EtA	58/42	30	6.7	24	18.7	17.2	95.6
	EtA	41/59	30	6.7	4	16.0	15.3	98.0
	EtA	41/59	30	6.7	24	25.7	25.1	95.3
	IPA	55/45	30	6.7	4	33.5	38.6	97.8
	IPA	55/45	30	6.7	20	54.9	98.7	91.8

	IPA	38/62	30	6.7	6	45.1	62.5	96.9
	IPA	38/62	30	6.7	20	58.7	98.0	88.1
	VA	59/41	30	6.7	1	32.0	35.1	97.4
	VA	59/41	30	6.7	6	52.6	85.2	93.6
	VA	59/41	30	6.7	20	60.7	98.3	74.3
	VA	42/58	30	6.7	1	39.3	47.2	96.7
	VA	42/58	30	6.7	6	56.5	95.5	90.1
	VA	42/58	30	6.7	20	66.1	97.7	66.8
	TFEB	47/53	30	6.7	20	61.9	77.2	81.0
	TFEB	47/53	30	6.7	24	61.6	76.1	81.0
	TFEB	31/69	30	6.7	20	59.5	71.3	80.4
	TFEB	31/69	30	6.7	24	62.9	80.5	81.4
	VP	55/45	30	6.7	6	62.7	86.7	81.8
	VP	55/45	30	6.7	24	66.8	99.2	82.6
	VP	38/62	30	6.7	6	61.6	93.8	82.4
	VP	38/62	30	6.7	24	68.2	99.0	82.7
<div><div>1</div><div>: (BA), (EPA), (EtA), (ETFA), (IPA), (VA), (EMA), 2,2,2- (TFEB), (VP)</div><div>2 B, ( L-2, c.f., C2, lyo (~10 U/mg, Roche Molecular Biochemicals) )</div></div>								

가

가 , , ( -40 ) , , 가 , 가 , ; (-17 ) 가 , 가 , 가 PM, PE, PnP, PnB PPh

[ 12 ]

	1	/ (v/v)	/	2 (mg/M $\varnothing$ )	( ) (%)	(S)- ee (%)	(R)- ee (%)
PE	IPA	51/49	1/1	6.7	20	51.6 72.4	95.6
	IPA	51/49	1/1	6.7	24	54.5 77.5	95.3

	VA	55/45	1/1	6.7	20	44.7	51.8	95.2
	VA	55/45	1/1	6.7	24	47.4	54.9	95.0
PnP	IPA	55/45	1/1	6.7	4	33.5	38.6	97.8
	IPA	55/45	1/1	6.7	20	54.9	98.7	91.8
	IPA	38/62	1/2	6.7	6	45.1	62.5	96.9
	IPA	38/62	1/2	6.7	20	58.7	98.0	88.1
	VA	59/41	1/1	6.7	1	32.0	35.1	97.4
	VA	59/41	1/1	6.7	6	52.6	85.2	93.6
	VA	59/41	1/1	6.7	20	60.7	98.3	74.3
	VA	42/58	1/2	6.7	1	39.3	47.2	96.7
	VA	42/58	1/2	6.7	6	56.5	95.5	90.1
	VA	42/58	1/2	6.7	20	66.1	97.7	66.8
PnB	IPA	57/43	1/1	6.7	4	40.1	53.3	96.7
	IPA	57/43	1/1	6.7	6	44.8	61.2	95.9
	IPA	57/43	1/1	6.7	20	58.0	99.5	81.7
	IPA	40/60	1/2	6.7	6	47.6	67.4	95.4
	IPA	40/60	1/2	6.7	20	58.7	>99	79.2
	IPA	40/60	1/2	6.7	24	60.3	>99	74.4
	VA	61/39	1/1	6.7	4	52.1	82.7	92.6
	VA	61/39	1/1	6.7	6	54.3	86.4	89.3
	VA	61/39	1/1	6.7	20	66.5	>99	56.7
	VA	44/56	1/2	6.7	2	38.5	51.5	95.2
	VA	44/56	1/2	6.7	6	55.9	>99	87.0
	VA	44/56	1/2	6.7	20	68.1	>99	53.5
PPh	IPA	57/43	1/1	6.7	6	29.8	51.3	96.4
	IPA	57/43	1/1	6.7	20	43.5	97.9	93.1
	IPA	57/43	1/1	6.7	24	44.1	98.2	92.0
	IPA	40/60	1/2	6.7	6	35.8	62.4	95.0
	IPA	40/60	1/2	6.7	20	44.5	96.1	90.5
	IPA	40/60	1/2	6.7	24	45.0	98.1	89.5
	VA	61/39	1/1	6.7	6	38.4	73.3	95.3
	VA	61/39	1/1	6.7	20	45.8	97.6	87.5
	VA	61/39	1/1	6.7	24	46.2	98.1	86.2
	VA	44/56	1/2	6.7	4	39.9	73.6	93.7
	VA	44/56	1/2	6.7	6	43.1	>99	92.8
	VA	44/56	1/2	6.7	20	47.6	98.1	81.7
<sup>1</sup> : (IPA) (VA) <sup>2</sup> B, ( L-2, c.f., C2, Iyo (~10 U/mg, Roche Molecular Biochemicals) )								

:

PM PPh CAL-B ( 80% 84% 가  
50% 가  
가  
13

[ 13 ]

		/	( )	<sup>1</sup> (mg/Mℓ)	( )	(%)	(S)- ee (%)	(R)- ee (%)
PM	VA	50/50	30	1.0	2	59.9	n.d. <sup>2</sup>	94.8
					22	84.3	n.d.	56.2
PM	VA	70/30	30	1.0	2	59.6	n.d.	94.3
					22	68.7	n.d.	81.6
PnB	VA	50/50	30	1.0	2	51.9	75.3	86.2
					22	70.5	99.0	47.6
PnB	VA	70/30	30	1.0	2	52.4	79.0	88.1
					6	59.9	99.0	76.3
PE	VA	50/50	30	1.0	4	39.6	95.7	95.7
					22	52.3	77.2	94.3
PE	VA	70/30	30	1.0	4	33.8	32.9	95.9
					22	39.6	45.4	95.7
PiP	VA	50/50	30	1.0	2	53.8	73.2	87.7
					22	65.4	95.1	73.2
PiP	VA	70/30	30	1.0	2	43.9	50.4	91.1
					22	63.6	96.9	79.4
PnP	VA	50/50	30	1.0	2	48.7	70.3	94.4
					22	67.6	99.0	59.7
PnP	VA	70/30	30	1.0	2	47.5	67.6	94.6
					5	58.4	95.4	89.0
PPh	VA	50/50	30	1.0	2	38.9	74.7	94.9
					22	52.5	99.0	68.0
PPh	VA	70/30	30	1.0	2	33.3	62.1	95.9
					6	46.0	99.0	92.2
PtB	VA	73/27	30	6.7	6	41.6	54.4	>99
					20	55.6	96.5	>99
PtB	VA	76/24	30	6.7	6	41.8	54.9	>99
					20	54.5	91.6	>99

<sup>1</sup> B ( L-2, Iyo (~120 U/mg, Roche Molecular Biochemicals) ). L-2, c.f., C2, Iyo (~10 U/mg, Roche Molecular Biochemicals) PtB .  
<sup>2</sup> n.d.

8

가

가 CAL-B

25, 35 45% (v/v) PMA 13 mg/Mℓ L-2, c.-f., C2 ( 10 U/mg) 0

.5 Mℓ 300 rpm 40 24

, . 35% 45% 3

(S)-PMA 92% ee , 25% PMA 6

(S)-PMA >96-98% ee 가 20% 25% 가

L-2, c.-f., C2 , (S)-PMA 20% 25%

30 97% ee .

PMA 25% (v/v) PMA 3500 (New Brunswick Scientific

) 1.5 . 26.6 mg/Mℓ L-2, c.-f., C2 ( 280 U/Mℓ) 가

, 25% PEA 2 5 15 .

CAL-B 가 . 15 가

PMA 가 . 15 (S)-PMA (R)-PM

가 >99.5% ee >85% ee .

CAL-B ( L-2, c.-f., C2; 240 U/Mℓ) PEA 가

15 , 3가 (<5 Mℓ) 1.5-L 가 20% (v/v) PEA

가 , 40 6 가

(S)-PEA

, 20% (v/v) PEA 3500 (New Brunswick Scientific) 1.5

2 9 30 CAL-B 가 , CA

L-B , 가 ) pH 7.2 37

(20% 가 , ( 가 18 7

가 PEA 32 ) 8 ( 가 10%) 8, 10, 16 25

PE (% ee ) (S)-PEA (R)-PE ) 8 (S)-PEA (R)-

L-2, c.-f., C2 ; 가

PPh

L-2, c.-f., C2 (6.6 mg/Mℓ) 1.0-L . <50%

70/30 76/30 PPh/VA % ee (R)-PPhA . >50%

, 70/30 PPh/VA 4

(S)-PPh (R)-PPhA >90% ee 95% ee .

5-8 .

PGEA 1.0- 가 (S)-PGA

E (R)-PGA



[ 14]

			/		%	CAL-B, L-2,		(S)-	(R)-
			(v/v)	( )	( %)	C2		ee (%)	ee (%)
						(mg/Mℓ)			
1	PM	VA	62/38	4	65 (68)	10.00	10	95.47	80.02
2	PM	IPA	69/31	4	40 (~43)	13.4	3	27.56	95.44
3	PnP	VA	69/31	4	65 (~63)	10	21	98.6	88.2
4	PnP	VA	78.5/21.5	4	40 (~44)	3.3-6.6	8	47.55	97.1
5	PnB	IPA	69/31	4	61 (~59)	6.7-18.6	7	99.9	92.1
6	PnB	IPA	73/27	4	50 (~45)	6.7	8	55.7	97.7
7	PtB	VA	73/27	24	60 (~56)	6.7	12	95.5	99.6
8	PPh	VA	76/24	20	56 (~45)	6.7	5	62.64	96.06
9	PPh	VA	70/30	4	66 (~51)	6.7	2	78.9	97.08

9

PMA

\_\_\_\_\_ :  
1.8 Mℓ L-2 C2 가 1-tert-PtB -2- (PtB), ( ) . 1  
00%

	( %)	(mg/Mℓ)		PtB	( μ L)	( μ L)	%
1	PMA 50%	13.4	PtB	500	500		104
2	PMA 70%	13.4	PtB	700	300		45
3	70%	13.4	PtB	700	300		70
4	70%	13.4	PtB	700	300		66

1.0 Mℓ PtB 4 , 1-tert- -2- 65 GC  
PM (PtBA), PMA  
\_\_\_\_\_ :  
15 DOWANOL PMA가 PtB (R)-PtBA  
(>99% ee) . (R)-PtB ,  
PMA 1 2 CAL-B가 (R)-PMA  
(R)-PM PtB (S)-PMA  
( , PtB) PMA (R)-PM

31% 20% PtB , 50:50 ( 1) 70:30 ( 2) PtB/PMA  
>99% ee R-PtBA , ,

15

[ 15]

	( )	(S) - PtB (% ee)	(R) - PtBA (% ee)	PtB (%) <sup>1</sup>	(R) - PM (% ee)	(S) - PMA (% ee)	PMA (%)
1	0	0	0	0	0	0	0
	18	22	>99	23	93	22	12
	24	25	>99	25	96	24	13
	47	32	>99	30	86	28	16
	65	34	>99	31	84	28	17
2	0	0	0	0	0	0	0
	18	13	>99	15	94	39	19
	24	15	>99	17	92	43	21
	47	17	>99	19	87	49	24
	65	18	>99	20	84	48	26
3	0	0	0	0	- <sup>2</sup>	-	-
	18	73	>99	49	-	-	-
	24	84	>99	53	-	-	-
	47	95	>99	56	-	-	-
	65	94	>99	56	-	-	-
4	0	0	0	0	-	-	-
	18	11	>99	13	-	-	-
	24	12	>99	15	-	-	-
	47	15	>99	17	-	-	-
	65	15	>99	17	-	-	-
<sup>1</sup> PtB PtBA , GC-FID ( ) [ PtBA/ PtBA+ PtB] x 100 <sup>2</sup>							

10

PMA

\_\_\_\_\_ :

PtB/PMA 30:70, 40:60, 50:50, 60:40 70:30  
R-PtBA, S-PtB, R-PM S-PMA  
PtB, PMA ( )  
1.8 Ml  
L-2 C2

	/ ( )	(mg/M $\ell$ )	PtB ( $\mu$ L)	PMA ( $\mu$ L)	(%)
1	PtB/PMA (30:70)	13.4	300	700	244.09
2	PtB/PMA (40:60)	13.4	400	600	156.91
3	PtB/PMA (50:50)	13.4	500	500	104.61
4	PtB/PMA (60:40)	13.4	600	400	69.74
5	PtB/PMA (70:30)	13.4	700	300	44.83

100% 4 48 GC PtB PtB, PtBA, PMA PM .

— :

(S)-PtB PtB/PMA PtB 가 >99% ee R-PtBA 가 PtB  
( 15 ). 30:70 PtB/PMA PtB  
가 PtB R-PMA R-PM  
S-PMA 가 16 .

[ 16 ]

	( )	(S)-PtB (% ee)	(R)-PtBA (% ee)	PtB (%) <sup>1</sup>	(R)-PM (% ee)	(S)-PMA (% ee)	PMA (%) <sup>2</sup>
1	0	1	71	1	91	1	0
	2	18	98	19	93	8	5
	5	36	>99	32	87	12	7
	20.5	57	>99	42	68	12	10
	51	52	>99	40	50	7	11
2	0	0	34	0	0	0	0
	2	16	>99	17	93	10	6
	5	30	>99	29	88	16	10
	20.5	45	>99	38	67	17	14
	51	50	>99	39	39	12	15
3	0	0	18	0	0	0	0
	2	12	>99	14	94	12	7
	5	23	98	24	90	21	12
	20.5	36	>99	33	72	25	17
	51	40	>99	34	49	19	19
4	0	0	8	0	0	0	0
	2	7	>99	8	93	10	6
	5	17	98	19	90	25	14
	20.5	28	>99	27	74	34	22



(S)-PtB가 1 >84% ee, (S)-PtB 3 65.6% ee  
 1 70% PtB >99% (R)-PtBA  
 PtB PMA  
 1.5, 3.0 4.5 66% ee 74% ee 1  
 (R)-PM  
 (R)-PM 2  
 (R)-PMA  
 가

[ 17 ]

	( )	(S)-PtB (% ee)	(R)-PtBA (% ee)	PtB (%) <sup>1</sup>	(S)-PMA (% ee)	PMA (%) <sup>2</sup>	(R)- PM (% ee) <sup>3</sup>
1	0	0	0	0	0	0	
	0.5	10	>99%	12	16	9	
	1	16	>99%	18	24	14	
	1.5	21	>99%	22	29	16	70
	1.75	22	>99%	27	7	3	
	2	35	>99%	34	12	7	
	2.5	40	>99%	38	14	8	
	3	44	>99%	40	15	9	74
	3.25	46	>99%	53	6	-- <sup>4</sup>	
	3.5	60	>99%	56	8	--	
	4	65	>99%	58	8	--	
	4.5	71	>99%	59	8	--	66
	4.75	68	>99%	67	4	--	
	20.5	85	99	70	3	--	
2	0	0	0	0	0	0	
	0.5	10	99	13	16	9	
	1	17	>99%	19	24	13	
	1.5	21	>99%	22	29	16	
	1.75	22	>99%	23	29	17	
	2	25	>99%	25	31	18	
	2.5	26	>99%	26	32	19	
	3	27	>99%	27	32	20	
	3.25	28	>99%	27	32	20	
	3.5	28	>99%	27	32	21	
	4	29	>99%	28	32	21	
	4.5	29	>99%	28	31	21	
	4.75	29	>99%	28	31	21	
	20.5	36	99	32	15	26	
3	0	0	0	0	0	0	
	0.5	10	>99%	12	15	8	
	1	17	>99%	18	23	13	

	1.5	21	>99%	22	28	16	
	1.75	22	>99%	23	12	8	
	2	29	>99%	28	15	9	
	2.5	33	>99%	30	17	11	
	3	36	>99%	32	18	12	
	3.25	37	>99%	33	11	8	
	3.5	41	>99%	35	12	8	
	4	44	>99%	37	13	9	
	4.5	47	>99%	38	13	9	
	4.75	47	>99%	38	9	7	
	20.5	66	99	46	6	9	

<sup>1</sup> PtB PtBA , GC-FID ( )  
[ PtBA/ PtBA+ PtB] x 100  
± 10% . 1 >50% PtB (>99% ee (R)-PtBA )  
PtB  
<sup>2</sup> PMA GC-FID ( ) [ PM/ PM+ PMA] x 100  
± 10% .  
<sup>3</sup> (R)-PM PM  
<sup>4</sup> nd, .

\_\_\_ B

\_\_\_ :

50:50 PtB/PMA 100 Mℓ PM  
. 50 Mℓ PMA A  
.

		(mg/Mℓ)		(mL)	(mL)	
1		40.2	PtB	50	50 <sup>1</sup>	1.5
2	#2	40.2	PtB	50	50 <sup>2</sup>	-
3	#3	40.2	PtB	50	50 <sup>3</sup>	-
<sup>1</sup>	1	50 Mℓ PMA	1.5, 3.0	4.5	PM -	.
<sup>2</sup>	2	50 Mℓ PMA				.
<sup>3</sup>	3		1	가	50 Mℓ PMA	.

\_\_\_ :

B ( 18) A . 1 3 PtB (R)-PtBA  
77% 43% . 50% 가 , 3 (PM)  
A , (R)-PtBA >99% ee  
1 (R)-PM (S)-PtB 5 >80% ee  
, 3 (S)-PtB 60% ee .

(R)-PM 3                      69% ee                      87% ee                      B                      1                      PtB                      1

[ 18 ]

	( )	(S)-PtB (% ee)	(R)-PtBA (% ee)	PtB (%) <sup>1</sup>	(S)-PMA (% ee)	PMA (%) <sup>2</sup>	(R)-PM (% ee) <sup>3</sup>
1	0	0	0	0	0	0	
	0.5	11	98	14	12	7	
	1	21	>99%	21	19	11	
	1.5	27	>99%	26	23	13	87
	2	45	>99%	46	10	4	
	2.5	55	>99%	50	11	5	
	3	59	>99%	51	11	5	70
	4	77	>99%	69	5	-- <sup>4</sup>	
	4.5	79	>99%	70	5	--	69
	5	80	>99%	76	3	--	
	5.5	80	>99%	76	3	--	
	6	83	>99%	77	3	--	
2	0	0	0	0	0	0	
	0.5	11	98	13	11	6	
	1	20	>99%	21	18	10	
	1.5	26	>99%	26	22	13	
	2	30	>99%	29	24	14	
	2.5	33	>99%	30	25	15	
	3	34	98	31	25	15	
	4	37	>99%	33	24	15	
	4.5	37	>99%	33	24	16	
	5	38	>99%	33	23	17	
	5.5	39	>99%	34	22	17	
	6	39	>99%	34	22	18	
3	0	0	0	0	0	0	
	0.5	10	98	13	11	6	
	1	19	99%	20	18	10	
	1.5	26	>99%	25	22	12	
	2	32	>99%	30	12	7	
	2.5	37	>99%	33	13	8	
	3	42	>99%	35	14	9	
	4	51	>99%	40	10	7	
	4.5	54	>99%	41	10	7	
	5	57	>99%	43	7	5	
	5.5	58	>99%	43	7	6	

	6	60	>99%	43	7	6	
<sup>1</sup> PtB	PtBA						, GC-FID ( )
[ PtBA/	PtBA+	PtB]	x 100				
± 10%	1	>50%	PtB	(>99% ee	(R)-PtBA		)
			PtB				
<sup>2</sup> PMA	GC-FID (						[ PM/ PM+ PMA] x 100
				± 10%			
<sup>3</sup>	(R)-PM				PM		
<sup>4</sup> nd,							

## 12

(R,S)-1-tert- -2- (S)-1,2-

(a): (R,S)-1-tert- -2-

366 Mℓ (R,S)-1-tert- -2- (PtB) 134 Mℓ 1.0-L  
 L-2 C2 3.35 g CAL-B 가 . 73:27 (PtB PtBA 60%  
 ) (R,S)-1-tert- -2- 500 Mℓ GC 30  
 20-24 20 5  
 0% 73:27 10 가 500 Mℓ (R,S)-1-tert- -2-  
 GC >99% ee (R)-1-tert- -2- (R-PtBA) >96%  
 ee (S)-1-tert- -2- (S-PtB) (b)

(b): (S)-PtB/(R)-PtBA

(a) 2 1  
 , 3790 g /(S)-PtB/(R)-PtBA 5-L  
 1/4' 2 (-15 SR-1  
 2/2 / 350 mmHg 47 가  
 3.5 (S)-PtB/(R)-PtBA 가 (S)-PtB/(R)-PtBA  
 1/4' 6 , 4033 g (S)-PtB/(R)-PtBA 5-L 2/1  
 / 6 36 mmHg 74 89 가 . 24  
 GC b ( 7-16) 1265 g 98.4%  
 (S)-PtB e ( 20-24) 1990 g 99.5% (R)-PtBA  
 ( , 200:1 ) (S)-PtB (R)-PtBA 가 >99.5% ee

(c-1): (S)-PtB (S)-PG

10 Mℓ 2 (b) 5.0032 g (S)-PtB 0.1888 g p- (p-T  
 SA) CaSO<sub>4</sub> 100 가 13  
 GC ( 18 ) . , (S)-PtB 98.6%가 (S)-PG  
 81.6% (200:1 ) (S)-PG GC  
 >99.5% ee

(c-2): (R)-PtBA (R)-PG 가



10 Ml 2 (b) 5.0375 g (R)-PtBA, 15.0919 g 0.4671 g  
p-TSA CaSO<sub>4</sub> 100 가 33  
GC ( 18 ). , (R)-PtBA 100%가 (R)-PG  
86.5% (200:1 ) (R)-PG GC  
>99.5% ee

(d): (S)-PG

5 Ml (c-1) 84-87 10 mmHg  
가 GC 89% PG  
GC MS  
PG (S)-PG ( , 200:1 ) GC  
>99.5% ee

(e): (S)-PtB 가

(b) (R)-PtBA (S)-PtB (S)-Pt 10 N  
B NaOH (S)-PtB 19 (c-1)  
(S)-1,2- >95% (99.5% ee)  
IR (S)-PtB  
(b)

[ 19 ]

	%	(R) %	(S)PG	( )	( )	%	( )
(S)-PtB	65.4	68.3		40-80	5.5	* 10.1	n.a. **
(S)-PtB	81	73.6		80	10.5	* 17	n.a. **
(S)-PtB	96.4	82.8		100	14.5	* 14	n.a. **
(S)-PtB	98.6	81.6		100	13	p-TSA 3.8	n.a. **
(S)-PtB (NaOH )	98.8	95.9		100	19	p-TSA 7.9	n.a. **
(R)-PtB	87.7	5.1		80	6.5	* 9.8	n.a. **
(R)-PtB	100	31.3		100	13.5	p-TSA 4.1	1
(R)-PtB	100	86.5		100	33	p-TSA 3.1	29
* DOWEX DR-2030							
( >2M)							
**							

(57)


1.

I

가

가

&lt; I&gt;



, R

2.

1 , 가 10% v/v .

3.

1 2 가 , R- 가 R-

4.

1 2 가 , S- 가 S-

5.

1 4 , R CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)  
2, C(CH<sub>3</sub>)<sub>3</sub> C<sub>6</sub>H<sub>5</sub> .

6.

1 4 , 가 가 .

7.

6 , 가 ( *Candida antarctica* ) B, LP 'S',  
( *Pseudomonas* ) , ( *Pseudomonas* )  
*pacia* ) .

8.

7 , 가 B .

9.

2 , 가 20% v/v .

10.

8 , 30% 50%가 가 .

11.

8 , 가 가 70% ee .

12.

3 , b) R- .

13.

3 ,

a) S- ;

b) S- S- .

14.  $4$ , b) S-


4 15. ,

a) R- ;

b) R- R-

16. 1, b)

**17.** 5% v/v                      II                      가                      ,  
                      ,                      가


 $\langle \quad || \rangle$  $\mathbb{R}$ 

18.  $\text{C}_{17}\text{H}_{35}$ , R  $\text{CH}_3$ ,  $\text{CH}_3\text{CH}_2$ ,  $\text{CH}_3(\text{CH}_2)_2$ ,  $\text{CH}_3(\text{CH}_2)_3$ ,  $\text{CH}(\text{CH}_3)_2$ ,  $\text{C}(\text{CH}_3)_3$  C

18. **19.** , 가 , , , 2,2,2-  
 , 2,2,2- , , , ,  
 , 1- , , , , ,

20. 19 , 가 .

21. 5% v/v II 가 ,  
가

 $\langle \quad || \rangle$  $\mathbb{R}$

22.

21  
6 H 5 , R CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub> C

23.

22 , 가 1- -2- (PMA), 1- -2-  
1- -2-

24.

18 22 , 가 가 .

25.

24 , 가 B .

26.

17 21 , 가 100% v/v .

27.

26 , 가, 50% .

28.

17 21 , 30% 50%가 .

29.

17 21 , 가 70% ee .

30.

17 21 ,

a) ;

b) .

31.

17 21 , .

32.

17 21 , .

33.

a) ( ) ;


b) 1 2 ;

c) 1 2 ;

d) II 1 1

, 2 , 2 1 , 가  
1 1 2

< II>



, R , , - , .

34.

33 , 1 1 2 2 100% .

35.

33 , R CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C<sub>6</sub>H<sub>5</sub>, C(CH<sub>3</sub>)<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, C(CH<sub>3</sub>)(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>, C(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, C<sub>6</sub>H<sub>5</sub>CH=CH<sub>2</sub>, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> CH<sub>2</sub>OCH<sub>3</sub> .

36.

33 ,

a) 1 ;

b) 1 .

37.

33 , 2 .

38.

33 , .

39.

33 ,

a) ;

b) 1 2 .

40.

(a) II 가 , , , (S)-1- -2- (R)-1- -2- ;


(b) (a) (S)-1- -2- (R)-1- -2- ;

(c) (b) (S)-1- -2- ( S)-1,2- ; (


(d) (c) (S)-1,2-

III .

< III>



< II >



, R , - , .

41.

40 ,

(e) (b) (R)-1- -2-  
(R)-1,2- ;

(f) (e) (R)-1,2-

.

42.

40 41 , R C(CH<sub>3</sub>)<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, C(CH<sub>3</sub>)(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>, C(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>CH=CH<sub>2</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> CH<sub>2</sub>OC<sub>6</sub>H<sub>5</sub> .

43.

42 , R C(CH<sub>3</sub>)<sub>3</sub> .

44.

40 43 , 가 가 .

45.

44 , 가 가 B .

46.

40 45 , (c) 가 p- .

47.

40 ,

(a) (R,S)-1-tert- -2- (S)-1-tert- -2- (R)-1-tert- B ,  
;

(b) (S)-1-tert- -2- (R)-1-tert- - ;

(c) (b) (S)-1-tert- -2- p-  
(S)-1,2- ;

(d) (c) (S)-1,2-

.

48.

44


- (e) (b) (R)-1-tert- - p-  
(R)-1,2- ;
- (f) (e) (R)-1,2-

49.


21

가


1



2




3







4A




4B




5





20% PEA의 거울상이성질체 선택적 가수분해 및  
고정화 CAL-B, 키라자임 L-2 C2에 의한 효소 계승환



8

